Meridian Health & Georgetown Lombardi Comprehensive Cancer Center Join New York Genome Center

Dec 20, 2019 | Genomics, New York Genomic Center, Oncology, Research

Meridian health & Georgetown Lombardi Comprehensive Cancer Center Join New York Genome Center

The New York Genome Center (NYGC) announced that Hackensack Meridien Health and Georgetown Lombardi Comprehensive Cancer Center have become the two newest institutional associate members of the NYGC.

What is the Significance of this?

Well, these are leading institutions with highly distinguished physician-scientists and researchers teaming up with the New York Genome Center. First, Hackensack Meridian Health is New Jersey’s largest health care network. For example, its Center for Discovery and Innovation (CDI) and John Theurer Cancer Center at Hackensack University Medical Center, a strong member of the Georgetown Lombardi consortium, are key components of the network’s strategy to develop and employ the latest genomic medicine for patients. And Georgetown Lombardi Comprehensive Cancer Center is Washington DC’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and NCI-approved consortium.

New Partnership

The new members are joining the NYGC through two separate partnerships with distinct collaborative research objectives. They include 1) an initiative led by Hackensack Meridian Health’s CDI focusing on exploring the genetics underlying the risk factors for behavioral disorders and identifying genetic markers that help physicians predict and manage these disorders more effectively; and 2) an initiative centering on cancer genomics and led by Georgetown Lombardi Comprehensive Cancer Center, which includes investigators from Georgetown University Medical Center, along with the Hackensack Meridian Health’s John Theurer Cancer Center and CDI. This partnership will seek to use advanced genetic analyses to better understand risk factors for emergence of certain aggressive cancers, such as pediatric brain tumors; why certain cancers fail to respond to immunotherapy; and identify genetic markers or cellular factors that can improve patient outcomes.

What is the New York Genome Center?

The New York Genome Center (NYGC) is an independent, nonprofit academic research institution focused on furthering genomic research that leads to scientific advances and new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer. They are organized to leverage their strengths in whole genome sequencing, genomic analysis, and development of new genomic tools, the NYGC serves as a nexus for collaboration in disease-focused genomic research for the New York medical and academic communities and beyond.

Harnessing Strengths

NYGC harnesses the expertise and builds on the combined strengths of their faculty, staff scientists, member institutions, scientific working groups, affiliate members, and industry partners to advance genomic discovery. Central to their scientific mission is an outstanding faculty who lead independent research labs based at the NYGC and hold joint tenure-track appointments with one of our member institutions.


Institutional founding members of the NYGC are: Cold Spring Harbor Laboratory, Columbia University, Albert Einstein College of Medicine, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, New York-Presbyterian Hospital, New York University, Northwell Health, The Rockefeller University, Stony Brook University, and Weill Cornell Medicine. Institutional associate members are: American Museum of Natural History, Georgetown Lombardi Comprehensive Cancer Center, Hackensack Meridian Health, Hospital for Special Surgery, The New York Stem Cell Foundation, Princeton University, and Roswell Park Cancer Institute.

Call to Action: Interested in learning more or doing business with the New York Genome Center? See the link or reach out to for partnering or tech/transfer opportunity.

Source: PR Newswire


Pin It on Pinterest